Northern Medical Program, University of Northern British Columbia, Prince George, British Columbia, Canada.
Exp Physiol. 2021 Feb;106(2):427-437. doi: 10.1113/EP088838. Epub 2020 Dec 17.
What is the central question of this study? Can chronic treatment of pituitary adenylate cyclase-activating polypeptide (PACAP) deficient mice with the melanocortin agonist melanotan II during cold acclimation rescue the impaired thermogenic capacity previously observed in PACAP deficient mice? What is the main finding and its importance? Using a genetic model of PACAP deficiency, this study provides evidence that PACAP acts upstream of the melanocortin system in regulating sympathetic nerve activity to brown adipose tissue in mice.
Impaired adipose tissue function in obesity, including reduced thermogenic potential, has detrimental consequences for metabolic health. Hormonal regulation of adaptive thermogenesis is being explored as a potential therapeutic target for human obesity. Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide expressed in nuclei of the hypothalamus known to regulate energy expenditure, and functional studies reveal a role for PACAP in the central regulation of thermogenesis, although mechanisms are not well understood. We hypothesized that PACAP acts upstream of the melanocortin system to regulate sympathetic nerve activity to stimulate thermogenesis. To assess this, female PACAP and PACAP mice were given daily peripheral injections of a melanocortin receptor agonist, melanotan II (MTII), for 3 weeks during cold acclimation, and the effect of MTII on thermogenic capacity and adipose tissue remodelling was examined by physiological and histological analyses. MTII partially rescued the impaired thermogenic capacity in PACAP mice as compared to PACAP mice as determined by measuring noradrenaline-induced metabolic rate. In addition, MTII treatment during cold acclimation corrected the previously identified deficit in lipid utilization in response to adrenergic stimulation in PACAP null mice, suggesting impaired lipid mobilization may contribute to the impaired thermogenic capacity of PACAP mice. Results presented here provide physiological evidence to suggest that PACAP acts upstream of melanocortin receptors to facilitate sympathetically induced mechanisms of adaptive thermogenesis in response to cold acclimation.
本研究的核心问题是什么?在冷适应过程中,用黑色素促激素激动剂黑色素 II 对垂体腺苷酸环化酶激活肽(PACAP)缺乏的小鼠进行慢性治疗,是否能挽救以前在 PACAP 缺乏的小鼠中观察到的产热能力受损?主要发现及其重要性是什么?本研究使用 PACAP 缺乏的遗传模型,提供了证据表明,PACAP 在调节小鼠棕色脂肪组织交感神经活性方面,作用于黑色素促激素系统的上游。
肥胖症中脂肪组织功能受损,包括产热潜力降低,对代谢健康有不利影响。激素调节适应性产热正被探索作为人类肥胖的潜在治疗靶点。垂体腺苷酸环化酶激活肽(PACAP)是一种在下丘脑核中表达的神经肽,已知其能调节能量消耗,功能研究表明 PACAP 在产热的中枢调节中发挥作用,尽管其机制尚不清楚。我们假设 PACAP 作用于黑色素促激素系统的上游,以调节交感神经活性来刺激产热。为了评估这一点,雌性 PACAP 和 PACAP 小鼠在冷适应期间每天接受外周注射黑色素促激素受体激动剂黑色素 II(MTII),通过生理和组织学分析,评估 MTII 对产热能力和脂肪组织重塑的影响。与 PACAP 小鼠相比,MTII 部分挽救了 PACAP 小鼠的产热能力受损,这是通过测量去甲肾上腺素诱导的代谢率来确定的。此外,在冷适应期间,MTII 治疗纠正了先前在 PACAP 缺失的小鼠中发现的对肾上腺素刺激的脂质利用缺陷,这表明脂质动员受损可能导致 PACAP 小鼠产热能力受损。这里呈现的结果提供了生理学证据,表明 PACAP 作用于黑色素促激素受体的上游,以促进冷适应时交感神经诱导的适应性产热机制。